U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT06843044) titled 'Efficacy and Safety of Ranquilon in Patients With Anxiety Disorders Due to Neurasthenia and Adaptation Disorders' on Feb. 17.
Brief Summary: Study is to evaluate the efficacy of the drug Ranquilon, 1 mg tablets, at a dosage of 6 mg/day compared to the drug Afobazole, 10 mg tablets, at a dosage of 30 mg/day for the treatment of patients with anxiety disorders due to neurasthenia and adaptation disorders.
Study Start Date: Jan. 13
Study Type: INTERVENTIONAL
Condition:
Anxiety
Neurasthenia
Adaptation Abnormal
Intervention:
DRUG: Ranquilon
1 mg tablets
DRUG: Afobazole
10 mg tablets
Recruitment Status: RECRUITING
Sponsor: Vale...